Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
PGA Tour goes to Dallas for same course and new title. LIV Golf plays in SingaporeAhead of the Paris Olympics, police clear a migrant camp near City HallNew Jersey and union ask judge to dismiss antiSelect list of nominees for 2024 Tony AwardsFacebook and Instagram face European Union scrutiny over possible breaches of digital rulebookUsing a walker boot for too long may mean you can't ever walk properly without it againHaiti prime minister: transitional council names new leaderBrazil soccer player Gabriel Barbosa cleared by CAS to play during appeal in doping rules caseFree child care from higher taxes? These cities subsidize daycareNew Jersey and union ask judge to dismiss anti
2.8858s , 6497.984375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Insights news portal